Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Andrew Rankin

Alan J Korman

Paul O Sheppard

Arvind Rajpal

Robert J Johnston

Guodong Chen

Ginger Chao Rakestraw

Richard Y Huang

Keith Sadoon Bahjat

Ekaterina G Deyanova

Lin Hui Su

Luis Borges

Xiaodi Deng

Mark J Selby

Nils Lonberg

Linda Liang

Michelle Minhua Han

Christine Bee

Xiao Min Schebye

Andy X Deng

Hong-An Truong

Joseph Toth

Jason Robert Pinckney

Diana Yuhui Chen

David A Critton

Akbar Nayeem

Michael Quigley

Hadia Lemar

Arathi Krishnakumar

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to VISTA at acidic pH

Antibodies binding to vista at acidic pH

Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

Growing community of inventors

Redwood City, CA, United States of America

Andrew Rankin